nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—blood vessel—stomach cancer	0.0134	0.116	CbGeAlD
Everolimus—MTOR—hematopoietic system—stomach cancer	0.00716	0.0615	CbGeAlD
Everolimus—MTOR—epithelium—stomach cancer	0.00654	0.0562	CbGeAlD
Everolimus—FKBP1A—hematopoietic system—stomach cancer	0.00644	0.0553	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—stomach cancer	0.0063	0.0542	CbGeAlD
Everolimus—FKBP1A—epithelium—stomach cancer	0.00588	0.0506	CbGeAlD
Everolimus—MTOR—pancreas—stomach cancer	0.00583	0.0501	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—stomach cancer	0.00567	0.0487	CbGeAlD
Everolimus—FKBP1A—pancreas—stomach cancer	0.00524	0.045	CbGeAlD
Everolimus—MTOR—lymphoid tissue—stomach cancer	0.00504	0.0433	CbGeAlD
Everolimus—MTOR—digestive system—stomach cancer	0.00498	0.0428	CbGeAlD
Everolimus—MTOR—bone marrow—stomach cancer	0.00459	0.0394	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—stomach cancer	0.00453	0.0389	CbGeAlD
Everolimus—FKBP1A—digestive system—stomach cancer	0.00448	0.0385	CbGeAlD
Everolimus—FKBP1A—bone marrow—stomach cancer	0.00413	0.0355	CbGeAlD
Everolimus—MTOR—endocrine gland—stomach cancer	0.00411	0.0353	CbGeAlD
Everolimus—MTOR—liver—stomach cancer	0.00371	0.0319	CbGeAlD
Everolimus—FKBP1A—endocrine gland—stomach cancer	0.0037	0.0318	CbGeAlD
Everolimus—FKBP1A—liver—stomach cancer	0.00334	0.0287	CbGeAlD
Everolimus—MTOR—lymph node—stomach cancer	0.00284	0.0244	CbGeAlD
Everolimus—FKBP1A—lymph node—stomach cancer	0.00256	0.022	CbGeAlD
Everolimus—CYP3A4—hematopoietic system—stomach cancer	0.0021	0.0181	CbGeAlD
Everolimus—CYP3A4—digestive system—stomach cancer	0.00146	0.0126	CbGeAlD
Everolimus—CYP3A4—endocrine gland—stomach cancer	0.00121	0.0104	CbGeAlD
Everolimus—CYP3A4—liver—stomach cancer	0.00109	0.00937	CbGeAlD
Everolimus—Paraesthesia—Docetaxel—stomach cancer	0.000162	0.000311	CcSEcCtD
Everolimus—Alopecia—Methotrexate—stomach cancer	0.000162	0.00031	CcSEcCtD
Everolimus—Dyspnoea—Docetaxel—stomach cancer	0.000161	0.000308	CcSEcCtD
Everolimus—Somnolence—Docetaxel—stomach cancer	0.00016	0.000308	CcSEcCtD
Everolimus—Mental disorder—Methotrexate—stomach cancer	0.00016	0.000308	CcSEcCtD
Everolimus—Eye disorder—Epirubicin—stomach cancer	0.00016	0.000307	CcSEcCtD
Everolimus—Erythema—Methotrexate—stomach cancer	0.000159	0.000306	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—stomach cancer	0.000159	0.000306	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—stomach cancer	0.000159	0.000305	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000159	0.000305	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—stomach cancer	0.000159	0.000305	CcSEcCtD
Everolimus—Flushing—Epirubicin—stomach cancer	0.000159	0.000305	CcSEcCtD
Everolimus—Vomiting—Fluorouracil—stomach cancer	0.000159	0.000305	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—stomach cancer	0.000159	0.000305	CcSEcCtD
Everolimus—Dyspepsia—Docetaxel—stomach cancer	0.000159	0.000305	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—stomach cancer	0.000158	0.000304	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—stomach cancer	0.000158	0.000304	CcSEcCtD
Everolimus—Insomnia—Capecitabine—stomach cancer	0.000158	0.000303	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—stomach cancer	0.000158	0.000302	CcSEcCtD
Everolimus—Rash—Fluorouracil—stomach cancer	0.000157	0.000302	CcSEcCtD
Everolimus—Dermatitis—Fluorouracil—stomach cancer	0.000157	0.000302	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—stomach cancer	0.000157	0.000302	CcSEcCtD
Everolimus—Paraesthesia—Capecitabine—stomach cancer	0.000157	0.000301	CcSEcCtD
Everolimus—Decreased appetite—Docetaxel—stomach cancer	0.000157	0.000301	CcSEcCtD
Everolimus—Headache—Fluorouracil—stomach cancer	0.000156	0.0003	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—stomach cancer	0.000156	0.0003	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—stomach cancer	0.000156	0.000299	CcSEcCtD
Everolimus—Dysgeusia—Methotrexate—stomach cancer	0.000156	0.000299	CcSEcCtD
Everolimus—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000156	0.000299	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—stomach cancer	0.000156	0.000299	CcSEcCtD
Everolimus—Dyspnoea—Capecitabine—stomach cancer	0.000156	0.000299	CcSEcCtD
Everolimus—Fatigue—Docetaxel—stomach cancer	0.000155	0.000298	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—stomach cancer	0.000155	0.000298	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—stomach cancer	0.000155	0.000298	CcSEcCtD
Everolimus—Nausea—Irinotecan—stomach cancer	0.000155	0.000297	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—stomach cancer	0.000155	0.000297	CcSEcCtD
Everolimus—Mediastinal disorder—Epirubicin—stomach cancer	0.000154	0.000296	CcSEcCtD
Everolimus—Pain—Docetaxel—stomach cancer	0.000154	0.000296	CcSEcCtD
Everolimus—Constipation—Docetaxel—stomach cancer	0.000154	0.000296	CcSEcCtD
Everolimus—Back pain—Methotrexate—stomach cancer	0.000154	0.000296	CcSEcCtD
Everolimus—Dyspepsia—Capecitabine—stomach cancer	0.000154	0.000295	CcSEcCtD
Everolimus—Chills—Epirubicin—stomach cancer	0.000154	0.000295	CcSEcCtD
Everolimus—Decreased appetite—Capecitabine—stomach cancer	0.000152	0.000291	CcSEcCtD
Everolimus—Alopecia—Epirubicin—stomach cancer	0.000151	0.00029	CcSEcCtD
Everolimus—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000151	0.000289	CcSEcCtD
Everolimus—Fatigue—Capecitabine—stomach cancer	0.00015	0.000289	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—stomach cancer	0.00015	0.000288	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—stomach cancer	0.00015	0.000288	CcSEcCtD
Everolimus—Pain—Capecitabine—stomach cancer	0.000149	0.000286	CcSEcCtD
Everolimus—Constipation—Capecitabine—stomach cancer	0.000149	0.000286	CcSEcCtD
Everolimus—Erythema—Epirubicin—stomach cancer	0.000149	0.000286	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—stomach cancer	0.000149	0.000286	CcSEcCtD
Everolimus—Feeling abnormal—Docetaxel—stomach cancer	0.000149	0.000285	CcSEcCtD
Everolimus—Nausea—Fluorouracil—stomach cancer	0.000148	0.000285	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—stomach cancer	0.000148	0.000284	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—stomach cancer	0.000148	0.000283	CcSEcCtD
Everolimus—Gastrointestinal pain—Docetaxel—stomach cancer	0.000147	0.000283	CcSEcCtD
Everolimus—Anaemia—Methotrexate—stomach cancer	0.000147	0.000282	CcSEcCtD
Everolimus—Flushing—Doxorubicin—stomach cancer	0.000147	0.000282	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—stomach cancer	0.000147	0.000282	CcSEcCtD
Everolimus—Flatulence—Epirubicin—stomach cancer	0.000147	0.000282	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—stomach cancer	0.000146	0.00028	CcSEcCtD
Everolimus—Back pain—Epirubicin—stomach cancer	0.000144	0.000277	CcSEcCtD
Everolimus—Feeling abnormal—Capecitabine—stomach cancer	0.000144	0.000276	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—stomach cancer	0.000144	0.000276	CcSEcCtD
Everolimus—Malaise—Methotrexate—stomach cancer	0.000144	0.000276	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—stomach cancer	0.000143	0.000275	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—stomach cancer	0.000143	0.000275	CcSEcCtD
Everolimus—Gastrointestinal pain—Capecitabine—stomach cancer	0.000143	0.000274	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—stomach cancer	0.000143	0.000274	CcSEcCtD
Everolimus—Body temperature increased—Docetaxel—stomach cancer	0.000142	0.000274	CcSEcCtD
Everolimus—Abdominal pain—Docetaxel—stomach cancer	0.000142	0.000274	CcSEcCtD
Everolimus—Leukopenia—Methotrexate—stomach cancer	0.000142	0.000274	CcSEcCtD
Everolimus—Chills—Doxorubicin—stomach cancer	0.000142	0.000273	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—stomach cancer	0.00014	0.000269	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—stomach cancer	0.00014	0.000269	CcSEcCtD
Everolimus—Cough—Methotrexate—stomach cancer	0.000139	0.000267	CcSEcCtD
Everolimus—Mental disorder—Doxorubicin—stomach cancer	0.000139	0.000266	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—stomach cancer	0.000138	0.000265	CcSEcCtD
Everolimus—Abdominal pain—Capecitabine—stomach cancer	0.000138	0.000265	CcSEcCtD
Everolimus—Body temperature increased—Capecitabine—stomach cancer	0.000138	0.000265	CcSEcCtD
Everolimus—Convulsion—Methotrexate—stomach cancer	0.000138	0.000265	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—stomach cancer	0.000138	0.000265	CcSEcCtD
Everolimus—Erythema—Doxorubicin—stomach cancer	0.000138	0.000265	CcSEcCtD
Everolimus—Anaemia—Epirubicin—stomach cancer	0.000138	0.000264	CcSEcCtD
Everolimus—Agitation—Epirubicin—stomach cancer	0.000137	0.000263	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—stomach cancer	0.000136	0.000261	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—stomach cancer	0.000135	0.00026	CcSEcCtD
Everolimus—Chest pain—Methotrexate—stomach cancer	0.000135	0.00026	CcSEcCtD
Everolimus—Myalgia—Methotrexate—stomach cancer	0.000135	0.00026	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—stomach cancer	0.000135	0.000259	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000135	0.000258	CcSEcCtD
Everolimus—Malaise—Epirubicin—stomach cancer	0.000134	0.000258	CcSEcCtD
Everolimus—Discomfort—Methotrexate—stomach cancer	0.000134	0.000257	CcSEcCtD
Everolimus—Syncope—Epirubicin—stomach cancer	0.000134	0.000256	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—stomach cancer	0.000133	0.000256	CcSEcCtD
Everolimus—Back pain—Doxorubicin—stomach cancer	0.000133	0.000256	CcSEcCtD
Everolimus—Hypersensitivity—Docetaxel—stomach cancer	0.000133	0.000255	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—stomach cancer	0.000132	0.000254	CcSEcCtD
Everolimus—Palpitations—Epirubicin—stomach cancer	0.000132	0.000253	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—stomach cancer	0.000131	0.000251	CcSEcCtD
Everolimus—Cough—Epirubicin—stomach cancer	0.00013	0.00025	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—stomach cancer	0.00013	0.000249	CcSEcCtD
Everolimus—Asthenia—Docetaxel—stomach cancer	0.000129	0.000248	CcSEcCtD
Everolimus—Convulsion—Epirubicin—stomach cancer	0.000129	0.000248	CcSEcCtD
Everolimus—Infection—Methotrexate—stomach cancer	0.000129	0.000248	CcSEcCtD
Everolimus—Hypertension—Epirubicin—stomach cancer	0.000129	0.000247	CcSEcCtD
Everolimus—Hypersensitivity—Capecitabine—stomach cancer	0.000129	0.000247	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—stomach cancer	0.000128	0.000245	CcSEcCtD
Everolimus—Pruritus—Docetaxel—stomach cancer	0.000128	0.000245	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—stomach cancer	0.000127	0.000245	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—stomach cancer	0.000127	0.000245	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—stomach cancer	0.000127	0.000244	CcSEcCtD
Everolimus—Chest pain—Epirubicin—stomach cancer	0.000127	0.000243	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—stomach cancer	0.000127	0.000243	CcSEcCtD
Everolimus—Myalgia—Epirubicin—stomach cancer	0.000127	0.000243	CcSEcCtD
Everolimus—Agitation—Doxorubicin—stomach cancer	0.000127	0.000243	CcSEcCtD
Everolimus—Anxiety—Epirubicin—stomach cancer	0.000126	0.000243	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—stomach cancer	0.000126	0.000242	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000126	0.000242	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—stomach cancer	0.000126	0.000241	CcSEcCtD
Everolimus—Discomfort—Epirubicin—stomach cancer	0.000125	0.000241	CcSEcCtD
Everolimus—Asthenia—Capecitabine—stomach cancer	0.000125	0.00024	CcSEcCtD
Everolimus—Malaise—Doxorubicin—stomach cancer	0.000124	0.000239	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—stomach cancer	0.000124	0.000238	CcSEcCtD
Everolimus—Anorexia—Methotrexate—stomach cancer	0.000124	0.000238	CcSEcCtD
Everolimus—Syncope—Doxorubicin—stomach cancer	0.000124	0.000237	CcSEcCtD
Everolimus—Pruritus—Capecitabine—stomach cancer	0.000123	0.000237	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—stomach cancer	0.000123	0.000237	CcSEcCtD
Everolimus—Diarrhoea—Docetaxel—stomach cancer	0.000123	0.000237	CcSEcCtD
Everolimus—Palpitations—Doxorubicin—stomach cancer	0.000122	0.000234	CcSEcCtD
Everolimus—Oedema—Epirubicin—stomach cancer	0.000122	0.000233	CcSEcCtD
Everolimus—Hypotension—Methotrexate—stomach cancer	0.000121	0.000233	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—stomach cancer	0.000121	0.000233	CcSEcCtD
Everolimus—Infection—Epirubicin—stomach cancer	0.000121	0.000232	CcSEcCtD
Everolimus—Cough—Doxorubicin—stomach cancer	0.00012	0.000231	CcSEcCtD
Everolimus—Shock—Epirubicin—stomach cancer	0.00012	0.00023	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—stomach cancer	0.000119	0.000229	CcSEcCtD
Everolimus—Diarrhoea—Capecitabine—stomach cancer	0.000119	0.000229	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—stomach cancer	0.000119	0.000229	CcSEcCtD
Everolimus—Dizziness—Docetaxel—stomach cancer	0.000119	0.000229	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—stomach cancer	0.000119	0.000228	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—stomach cancer	0.000119	0.000228	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—stomach cancer	0.000119	0.000228	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000118	0.000227	CcSEcCtD
Everolimus—Skin disorder—Epirubicin—stomach cancer	0.000118	0.000227	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—stomach cancer	0.000118	0.000226	CcSEcCtD
Everolimus—Insomnia—Methotrexate—stomach cancer	0.000117	0.000226	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—stomach cancer	0.000117	0.000225	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—stomach cancer	0.000117	0.000225	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—stomach cancer	0.000117	0.000225	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—stomach cancer	0.000117	0.000224	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—stomach cancer	0.000117	0.000224	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000117	0.000224	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—stomach cancer	0.000116	0.000223	CcSEcCtD
Everolimus—Anorexia—Epirubicin—stomach cancer	0.000116	0.000222	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—stomach cancer	0.000116	0.000222	CcSEcCtD
Everolimus—Somnolence—Methotrexate—stomach cancer	0.000115	0.000222	CcSEcCtD
Everolimus—Dizziness—Capecitabine—stomach cancer	0.000115	0.000222	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—stomach cancer	0.000115	0.00022	CcSEcCtD
Everolimus—Vomiting—Docetaxel—stomach cancer	0.000115	0.00022	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—stomach cancer	0.000114	0.00022	CcSEcCtD
Everolimus—Rash—Docetaxel—stomach cancer	0.000114	0.000218	CcSEcCtD
Everolimus—Hypotension—Epirubicin—stomach cancer	0.000114	0.000218	CcSEcCtD
Everolimus—Dermatitis—Docetaxel—stomach cancer	0.000114	0.000218	CcSEcCtD
Everolimus—Decreased appetite—Methotrexate—stomach cancer	0.000113	0.000217	CcSEcCtD
Everolimus—Headache—Docetaxel—stomach cancer	0.000113	0.000217	CcSEcCtD
Everolimus—Oedema—Doxorubicin—stomach cancer	0.000112	0.000216	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000112	0.000215	CcSEcCtD
Everolimus—Fatigue—Methotrexate—stomach cancer	0.000112	0.000215	CcSEcCtD
Everolimus—Infection—Doxorubicin—stomach cancer	0.000112	0.000215	CcSEcCtD
Everolimus—Pain—Methotrexate—stomach cancer	0.000111	0.000213	CcSEcCtD
Everolimus—Vomiting—Capecitabine—stomach cancer	0.000111	0.000213	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000111	0.000213	CcSEcCtD
Everolimus—Shock—Doxorubicin—stomach cancer	0.000111	0.000212	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—stomach cancer	0.00011	0.000212	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—stomach cancer	0.00011	0.000211	CcSEcCtD
Everolimus—Rash—Capecitabine—stomach cancer	0.00011	0.000211	CcSEcCtD
Everolimus—Insomnia—Epirubicin—stomach cancer	0.00011	0.000211	CcSEcCtD
Everolimus—Dermatitis—Capecitabine—stomach cancer	0.00011	0.000211	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—stomach cancer	0.00011	0.000211	CcSEcCtD
Everolimus—Headache—Capecitabine—stomach cancer	0.000109	0.00021	CcSEcCtD
Everolimus—Skin disorder—Doxorubicin—stomach cancer	0.000109	0.00021	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—stomach cancer	0.000109	0.00021	CcSEcCtD
Everolimus—Hyperhidrosis—Doxorubicin—stomach cancer	0.000109	0.000209	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—stomach cancer	0.000108	0.000208	CcSEcCtD
Everolimus—Somnolence—Epirubicin—stomach cancer	0.000108	0.000207	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—stomach cancer	0.000107	0.000206	CcSEcCtD
Everolimus—Nausea—Docetaxel—stomach cancer	0.000107	0.000206	CcSEcCtD
Everolimus—Feeling abnormal—Methotrexate—stomach cancer	0.000107	0.000205	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—stomach cancer	0.000107	0.000205	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—stomach cancer	0.000106	0.000204	CcSEcCtD
Everolimus—Decreased appetite—Epirubicin—stomach cancer	0.000106	0.000203	CcSEcCtD
Everolimus—Hypotension—Doxorubicin—stomach cancer	0.000105	0.000202	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000105	0.000201	CcSEcCtD
Everolimus—Fatigue—Epirubicin—stomach cancer	0.000105	0.000201	CcSEcCtD
Everolimus—Pain—Epirubicin—stomach cancer	0.000104	0.0002	CcSEcCtD
Everolimus—Constipation—Epirubicin—stomach cancer	0.000104	0.0002	CcSEcCtD
Everolimus—Nausea—Capecitabine—stomach cancer	0.000104	0.000199	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—stomach cancer	0.000103	0.000197	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—stomach cancer	0.000103	0.000197	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000102	0.000197	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—stomach cancer	0.000102	0.000195	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—stomach cancer	0.000101	0.000194	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—stomach cancer	0.0001	0.000193	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—stomach cancer	0.0001	0.000192	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—stomach cancer	0.0001	0.000192	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—stomach cancer	9.94e-05	0.000191	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—stomach cancer	9.9e-05	0.00019	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—stomach cancer	9.78e-05	0.000188	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—stomach cancer	9.71e-05	0.000186	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—stomach cancer	9.7e-05	0.000186	CcSEcCtD
Everolimus—Pain—Doxorubicin—stomach cancer	9.62e-05	0.000185	CcSEcCtD
Everolimus—Constipation—Doxorubicin—stomach cancer	9.62e-05	0.000185	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—stomach cancer	9.61e-05	0.000184	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—stomach cancer	9.61e-05	0.000184	CcSEcCtD
Everolimus—Hypersensitivity—Methotrexate—stomach cancer	9.57e-05	0.000184	CcSEcCtD
Everolimus—Asthenia—Methotrexate—stomach cancer	9.32e-05	0.000179	CcSEcCtD
Everolimus—Feeling abnormal—Doxorubicin—stomach cancer	9.27e-05	0.000178	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—stomach cancer	9.2e-05	0.000177	CcSEcCtD
Everolimus—Pruritus—Methotrexate—stomach cancer	9.19e-05	0.000176	CcSEcCtD
Everolimus—Hypersensitivity—Epirubicin—stomach cancer	8.96e-05	0.000172	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—stomach cancer	8.89e-05	0.000171	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—stomach cancer	8.89e-05	0.000171	CcSEcCtD
Everolimus—Diarrhoea—Methotrexate—stomach cancer	8.89e-05	0.000171	CcSEcCtD
Everolimus—Asthenia—Epirubicin—stomach cancer	8.72e-05	0.000167	CcSEcCtD
Everolimus—Pruritus—Epirubicin—stomach cancer	8.6e-05	0.000165	CcSEcCtD
Everolimus—Dizziness—Methotrexate—stomach cancer	8.59e-05	0.000165	CcSEcCtD
Everolimus—Diarrhoea—Epirubicin—stomach cancer	8.32e-05	0.00016	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—stomach cancer	8.29e-05	0.000159	CcSEcCtD
Everolimus—Vomiting—Methotrexate—stomach cancer	8.26e-05	0.000159	CcSEcCtD
Everolimus—Rash—Methotrexate—stomach cancer	8.19e-05	0.000157	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—stomach cancer	8.18e-05	0.000157	CcSEcCtD
Everolimus—Headache—Methotrexate—stomach cancer	8.14e-05	0.000156	CcSEcCtD
Everolimus—Asthenia—Doxorubicin—stomach cancer	8.07e-05	0.000155	CcSEcCtD
Everolimus—Dizziness—Epirubicin—stomach cancer	8.04e-05	0.000154	CcSEcCtD
Everolimus—Pruritus—Doxorubicin—stomach cancer	7.96e-05	0.000153	CcSEcCtD
Everolimus—Vomiting—Epirubicin—stomach cancer	7.73e-05	0.000148	CcSEcCtD
Everolimus—Nausea—Methotrexate—stomach cancer	7.72e-05	0.000148	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—stomach cancer	7.7e-05	0.000148	CcSEcCtD
Everolimus—Rash—Epirubicin—stomach cancer	7.66e-05	0.000147	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—stomach cancer	7.66e-05	0.000147	CcSEcCtD
Everolimus—Headache—Epirubicin—stomach cancer	7.62e-05	0.000146	CcSEcCtD
Everolimus—Dizziness—Doxorubicin—stomach cancer	7.44e-05	0.000143	CcSEcCtD
Everolimus—Nausea—Epirubicin—stomach cancer	7.22e-05	0.000139	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—stomach cancer	7.17e-05	0.000198	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—stomach cancer	7.15e-05	0.000137	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—IL6—stomach cancer	7.13e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6ST—stomach cancer	7.13e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RGS2—stomach cancer	7.12e-05	0.000196	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GAST—stomach cancer	7.12e-05	0.000196	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—stomach cancer	7.11e-05	0.000196	CbGpPWpGaD
Everolimus—Rash—Doxorubicin—stomach cancer	7.09e-05	0.000136	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—stomach cancer	7.09e-05	0.000136	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—stomach cancer	7.05e-05	0.000194	CbGpPWpGaD
Everolimus—Headache—Doxorubicin—stomach cancer	7.05e-05	0.000135	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTP1—stomach cancer	7.01e-05	0.000193	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD44—stomach cancer	7.01e-05	0.000193	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADRB2—stomach cancer	7e-05	0.000193	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTP1—stomach cancer	6.92e-05	0.000191	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MAPK1—stomach cancer	6.9e-05	0.00019	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PRKCB—stomach cancer	6.88e-05	0.00019	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PPP2R1A—stomach cancer	6.86e-05	0.000189	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6ST—stomach cancer	6.82e-05	0.000188	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK3—stomach cancer	6.8e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—stomach cancer	6.75e-05	0.000186	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGG—stomach cancer	6.75e-05	0.000186	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—stomach cancer	6.68e-05	0.000128	CcSEcCtD
Everolimus—MTOR—Disease—RPS6—stomach cancer	6.62e-05	0.000183	CbGpPWpGaD
Everolimus—MTOR—Immune System—HBEGF—stomach cancer	6.59e-05	0.000182	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APC—stomach cancer	6.55e-05	0.000181	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKAA1—stomach cancer	6.49e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Disease—CD44—stomach cancer	6.47e-05	0.000178	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK1—stomach cancer	6.47e-05	0.000178	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—stomach cancer	6.47e-05	0.000178	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—stomach cancer	6.46e-05	0.000178	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTM1—stomach cancer	6.45e-05	0.000178	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CASP8—stomach cancer	6.38e-05	0.000176	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SMAD4—stomach cancer	6.37e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6R—stomach cancer	6.36e-05	0.000175	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—stomach cancer	6.36e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RBP4—stomach cancer	6.27e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—stomach cancer	6.11e-05	0.000168	CbGpPWpGaD
Everolimus—MTOR—Disease—HBEGF—stomach cancer	6.09e-05	0.000168	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6R—stomach cancer	6.08e-05	0.000168	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDH1—stomach cancer	6.06e-05	0.000167	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FYN—stomach cancer	6.04e-05	0.000167	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACAD8—stomach cancer	6.03e-05	0.000166	CbGpPWpGaD
Everolimus—MTOR—Immune System—PPP2R1A—stomach cancer	5.96e-05	0.000164	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—stomach cancer	5.79e-05	0.00016	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SERPINE1—stomach cancer	5.7e-05	0.000157	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR2—stomach cancer	5.67e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—stomach cancer	5.61e-05	0.000155	CbGpPWpGaD
Everolimus—MTOR—Disease—PPP2R1A—stomach cancer	5.51e-05	0.000152	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RHOA—stomach cancer	5.5e-05	0.000152	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—stomach cancer	5.44e-05	0.00015	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HSPB1—stomach cancer	5.39e-05	0.000149	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR2—stomach cancer	5.39e-05	0.000149	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GMPR2—stomach cancer	5.38e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2R—stomach cancer	5.33e-05	0.000147	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BMP2—stomach cancer	5.33e-05	0.000147	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB2—stomach cancer	5.32e-05	0.000147	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—stomach cancer	5.3e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Immune System—FYN—stomach cancer	5.26e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKR1C3—stomach cancer	5.25e-05	0.000145	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS2—stomach cancer	5.2e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—stomach cancer	5.19e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR1A—stomach cancer	5.19e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Disease—SMAD4—stomach cancer	5.11e-05	0.000141	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—stomach cancer	5.11e-05	0.000141	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—stomach cancer	5.09e-05	0.00014	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CAV1—stomach cancer	5.04e-05	0.000139	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOA1—stomach cancer	5.03e-05	0.000139	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ANXA1—stomach cancer	5.01e-05	0.000138	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—stomach cancer	4.97e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—stomach cancer	4.97e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR2—stomach cancer	4.94e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1B—stomach cancer	4.93e-05	0.000136	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH3B—stomach cancer	4.92e-05	0.000136	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SUCLG1—stomach cancer	4.92e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB1—stomach cancer	4.86e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Disease—FYN—stomach cancer	4.85e-05	0.000134	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PRKCB—stomach cancer	4.79e-05	0.000132	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6ST—stomach cancer	4.78e-05	0.000132	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1B—stomach cancer	4.73e-05	0.00013	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1B—stomach cancer	4.71e-05	0.00013	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—JUN—stomach cancer	4.69e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Disease—ERCC2—stomach cancer	4.67e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RPS6—stomach cancer	4.64e-05	0.000128	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—stomach cancer	4.59e-05	0.000126	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NDUFV1—stomach cancer	4.57e-05	0.000126	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NDUFS1—stomach cancer	4.57e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR2—stomach cancer	4.56e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—stomach cancer	4.55e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS2—stomach cancer	4.52e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK8—stomach cancer	4.44e-05	0.000122	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—stomach cancer	4.39e-05	0.000121	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—stomach cancer	4.37e-05	0.00012	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—stomach cancer	4.35e-05	0.00012	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HBEGF—stomach cancer	4.26e-05	0.000118	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6R—stomach cancer	4.26e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS2—stomach cancer	4.17e-05	0.000115	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCB—stomach cancer	4.17e-05	0.000115	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6ST—stomach cancer	4.15e-05	0.000115	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BLVRB—stomach cancer	4.07e-05	0.000112	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PGLS—stomach cancer	4.07e-05	0.000112	CbGpPWpGaD
Everolimus—MTOR—Disease—CAV1—stomach cancer	4.05e-05	0.000112	CbGpPWpGaD
Everolimus—MTOR—Disease—APOA1—stomach cancer	4.04e-05	0.000111	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—stomach cancer	3.99e-05	0.00011	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB2—stomach cancer	3.93e-05	0.000108	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPAP2A—stomach cancer	3.89e-05	0.000107	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—stomach cancer	3.88e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK3—stomach cancer	3.88e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PPP2R1A—stomach cancer	3.86e-05	0.000106	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RHOA—stomach cancer	3.85e-05	0.000106	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6ST—stomach cancer	3.84e-05	0.000106	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—stomach cancer	3.81e-05	0.000105	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—stomach cancer	3.72e-05	0.000102	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK3—stomach cancer	3.71e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6R—stomach cancer	3.71e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK1—stomach cancer	3.69e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—stomach cancer	3.69e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—stomach cancer	3.69e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—stomach cancer	3.67e-05	0.000101	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—stomach cancer	3.61e-05	9.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMAD4—stomach cancer	3.58e-05	9.87e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—stomach cancer	3.56e-05	9.82e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—stomach cancer	3.54e-05	9.76e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK1—stomach cancer	3.53e-05	9.72e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—stomach cancer	3.53e-05	9.72e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—stomach cancer	3.48e-05	9.6e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CKB—stomach cancer	3.46e-05	9.55e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NDUFA2—stomach cancer	3.46e-05	9.55e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FBP1—stomach cancer	3.46e-05	9.55e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA1—stomach cancer	3.46e-05	9.55e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6R—stomach cancer	3.42e-05	9.43e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FYN—stomach cancer	3.4e-05	9.37e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—stomach cancer	3.38e-05	9.31e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—stomach cancer	3.35e-05	9.22e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—stomach cancer	3.33e-05	9.18e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—stomach cancer	3.3e-05	9.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLIN2—stomach cancer	3.26e-05	8.98e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—stomach cancer	3.2e-05	8.83e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—stomach cancer	3.2e-05	8.82e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR2—stomach cancer	3.19e-05	8.8e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA2—stomach cancer	3.17e-05	8.73e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—stomach cancer	3.15e-05	8.68e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—stomach cancer	3.14e-05	8.66e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—stomach cancer	3.1e-05	8.54e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—RHOA—stomach cancer	3.09e-05	8.52e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NT5E—stomach cancer	3.09e-05	8.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PGAM1—stomach cancer	3.09e-05	8.51e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—stomach cancer	3.07e-05	8.47e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—stomach cancer	3.06e-05	8.44e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—stomach cancer	3.06e-05	8.43e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—stomach cancer	3.06e-05	8.42e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—stomach cancer	3.04e-05	8.39e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK8—stomach cancer	2.97e-05	8.19e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—stomach cancer	2.96e-05	8.16e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCE1—stomach cancer	2.95e-05	8.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH7A1—stomach cancer	2.95e-05	8.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS2—stomach cancer	2.92e-05	8.05e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1B—stomach cancer	2.87e-05	7.91e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—stomach cancer	2.86e-05	7.89e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—stomach cancer	2.84e-05	7.84e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—stomach cancer	2.83e-05	7.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CAV1—stomach cancer	2.83e-05	7.81e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—stomach cancer	2.83e-05	7.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOA1—stomach cancer	2.83e-05	7.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UMPS—stomach cancer	2.82e-05	7.78e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—stomach cancer	2.82e-05	7.77e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—stomach cancer	2.8e-05	7.71e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—stomach cancer	2.74e-05	7.56e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—stomach cancer	2.73e-05	7.53e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—stomach cancer	2.72e-05	7.49e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—stomach cancer	2.71e-05	7.47e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCB—stomach cancer	2.7e-05	7.43e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6ST—stomach cancer	2.69e-05	7.4e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—stomach cancer	2.65e-05	7.3e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—stomach cancer	2.65e-05	7.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PDHA1—stomach cancer	2.63e-05	7.24e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ECHS1—stomach cancer	2.63e-05	7.24e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK3—stomach cancer	2.6e-05	7.16e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK8—stomach cancer	2.59e-05	7.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—stomach cancer	2.58e-05	7.11e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—stomach cancer	2.52e-05	6.96e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK1—stomach cancer	2.47e-05	6.81e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—stomach cancer	2.47e-05	6.81e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FADS1—stomach cancer	2.47e-05	6.8e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMP—stomach cancer	2.47e-05	6.8e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—stomach cancer	2.45e-05	6.74e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6R—stomach cancer	2.4e-05	6.61e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—stomach cancer	2.36e-05	6.52e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—stomach cancer	2.33e-05	6.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SREBF2—stomach cancer	2.31e-05	6.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RORA—stomach cancer	2.28e-05	6.3e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK3—stomach cancer	2.26e-05	6.22e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—stomach cancer	2.24e-05	6.19e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—stomach cancer	2.18e-05	6.02e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RHOA—stomach cancer	2.16e-05	5.97e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK1—stomach cancer	2.15e-05	5.92e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—stomach cancer	2.15e-05	5.92e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—stomach cancer	2.14e-05	5.91e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—stomach cancer	2.14e-05	5.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDOB—stomach cancer	2.14e-05	5.9e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK3—stomach cancer	2.08e-05	5.75e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—stomach cancer	2.07e-05	5.72e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—stomach cancer	2.03e-05	5.59e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—stomach cancer	2.03e-05	5.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—stomach cancer	2e-05	5.52e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX5—stomach cancer	1.99e-05	5.48e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK1—stomach cancer	1.98e-05	5.47e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—stomach cancer	1.98e-05	5.47e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—stomach cancer	1.98e-05	5.47e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DPYD—stomach cancer	1.96e-05	5.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—stomach cancer	1.9e-05	5.24e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—stomach cancer	1.9e-05	5.23e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—stomach cancer	1.87e-05	5.16e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—stomach cancer	1.86e-05	5.14e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—stomach cancer	1.86e-05	5.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—stomach cancer	1.77e-05	4.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—stomach cancer	1.77e-05	4.87e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—stomach cancer	1.73e-05	4.77e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—stomach cancer	1.72e-05	4.75e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—stomach cancer	1.72e-05	4.75e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—stomach cancer	1.72e-05	4.74e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—stomach cancer	1.71e-05	4.72e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2A6—stomach cancer	1.71e-05	4.72e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK8—stomach cancer	1.67e-05	4.61e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C3—stomach cancer	1.66e-05	4.59e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—stomach cancer	1.65e-05	4.55e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO1—stomach cancer	1.62e-05	4.47e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—stomach cancer	1.59e-05	4.39e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—stomach cancer	1.54e-05	4.25e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—stomach cancer	1.53e-05	4.21e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—stomach cancer	1.52e-05	4.2e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK3—stomach cancer	1.46e-05	4.02e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD44—stomach cancer	1.44e-05	3.96e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—stomach cancer	1.42e-05	3.91e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK1—stomach cancer	1.39e-05	3.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—stomach cancer	1.39e-05	3.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—stomach cancer	1.31e-05	3.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP2R1A—stomach cancer	1.22e-05	3.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—stomach cancer	1.21e-05	3.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—stomach cancer	1.2e-05	3.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—stomach cancer	1.18e-05	3.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—stomach cancer	1.17e-05	3.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—stomach cancer	1.12e-05	3.07e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—stomach cancer	1.12e-05	3.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—stomach cancer	1.1e-05	3.04e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—stomach cancer	1.07e-05	2.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ERCC2—stomach cancer	1.04e-05	2.86e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—stomach cancer	9.74e-06	2.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAV1—stomach cancer	8.99e-06	2.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA1—stomach cancer	8.97e-06	2.47e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—stomach cancer	7.9e-06	2.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—stomach cancer	7.1e-06	1.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—stomach cancer	6.79e-06	1.87e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—stomach cancer	6.21e-06	1.71e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—stomach cancer	3.82e-06	1.05e-05	CbGpPWpGaD
